X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
edoxaban (923) 923
index medicus (584) 584
rivaroxaban (542) 542
apixaban (513) 513
dabigatran (484) 484
warfarin (479) 479
humans (440) 440
anticoagulants (367) 367
atrial fibrillation (353) 353
administration, oral (235) 235
stroke (218) 218
cardiac & cardiovascular systems (209) 209
venous thromboembolism (200) 200
anticoagulants - therapeutic use (183) 183
peripheral vascular disease (180) 180
hematology (179) 179
thromboembolism (173) 173
male (163) 163
factor xa inhibitor (156) 156
atrial fibrillation - drug therapy (153) 153
safety (153) 153
anticoagulants - administration & dosage (149) 149
anticoagulants - adverse effects (147) 147
atrial-fibrillation (147) 147
female (147) 147
prevention (133) 133
pharmacology & pharmacy (125) 125
aged (123) 123
risk factors (113) 113
stroke prevention (113) 113
treatment outcome (113) 113
anticoagulation (111) 111
bleeding (111) 111
stroke - prevention & control (111) 111
hemorrhage - chemically induced (109) 109
atrial fibrillation - complications (106) 106
direct oral anticoagulants (106) 106
dabigatran etexilate (100) 100
pharmacokinetics (100) 100
oral anticoagulants (98) 98
risk (98) 98
middle aged (93) 93
analysis (92) 92
efficacy (90) 90
pyridines - therapeutic use (90) 90
thiazoles - therapeutic use (89) 89
thrombosis (89) 89
cardiac arrhythmia (86) 86
management (84) 84
pyridines - administration & dosage (84) 84
thiazoles - administration & dosage (84) 84
thrombin (82) 82
patients (80) 80
medicine, general & internal (78) 78
factor xa inhibitors - therapeutic use (77) 77
medicine & public health (74) 74
therapy (74) 74
warfarin - therapeutic use (74) 74
venous thromboembolism - drug therapy (73) 73
cardiology (72) 72
stroke - etiology (70) 70
blood coagulation - drug effects (68) 68
clinical trials (68) 68
pyridines - adverse effects (68) 68
thiazoles - adverse effects (68) 68
abridged index medicus (67) 67
hemorrhage (63) 63
drug therapy (62) 62
care and treatment (61) 61
mortality (61) 61
factor xa inhibitors - administration & dosage (60) 60
factor xa inhibitors (59) 59
pharmacodynamics (57) 57
review (55) 55
fibrillation (54) 54
antithrombotic therapy (52) 52
pulmonary embolism (52) 52
randomized controlled trials as topic (51) 51
aged, 80 and over (50) 50
direct thrombin inhibitor (50) 50
factor xa inhibitors - adverse effects (50) 50
cancer (47) 47
vitamin k - antagonists & inhibitors (47) 47
warfarin - adverse effects (47) 47
anticoagulant (46) 46
internal medicine (46) 46
adult (45) 45
anticoagulants - pharmacokinetics (45) 45
metaanalysis (45) 45
nonvalvular atrial-fibrillation (45) 45
dose-response relationship, drug (44) 44
deep-vein thrombosis (43) 43
reversal (43) 43
health risk assessment (42) 42
pyrazoles - therapeutic use (42) 42
pyridones - therapeutic use (42) 42
animals (41) 41
anticoagulants - pharmacology (41) 41
cardiovascular diseases (41) 41
prothrombin complex concentrate (41) 41
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (859) 859
German (28) 28
Japanese (21) 21
French (15) 15
Spanish (11) 11
Hungarian (6) 6
Portuguese (5) 5
Russian (5) 5
Italian (3) 3
Czech (2) 2
Polish (2) 2
Chinese (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 20, pp. 2017 - 2023
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment... 
ANTICOAGULANTS | ONCOLOGY | WARFARIN | THROMBOSIS | RIVAROXABAN | PREVENTION | EDOXABAN | K-ANTAGONIST | BLEEDING COMPLICATIONS
Journal Article
Circulation journal : official journal of the Japanese Circulation Society, ISSN 1346-9843, 05/2019, Volume 83, Issue 6, pp. 1394 - 1404
Background: ETNA-VTE-Japan is an ongoing prospective observational study conducted as part of a postmarketing observational study to investigate the safety and... 
Edoxaban | Postmarketing observational study | Bleeding adverse events | Japan | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | XA INHIBITOR EDOXABAN | ANTAGONIST ORAL ANTICOAGULANTS | BLEEDING EVENTS | APIXABAN
Journal Article
European Heart Journal, ISSN 0195-668X, 05/2018, Volume 39, Issue 19, pp. 1657 - 1660
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 2018, Volume 118, Issue 8, pp. 1439 - 1449
In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding... 
Stroke, Systemic or Venous Thromboembolism | direct oral anticoagulants | cancer | anticoagulant treatment | major bleeding | venous thromboembolism | THERAPY | RIVAROXABAN | EDOXABAN | PATTERNS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY
Journal Article
Nihon Kessen Shiketsu Gakkai shi, ISSN 0915-7441, 2017, Volume 28, Issue 1, pp. 50 - 54
Abstract: Background: The direct anti-Xa agent edoxaban was approved in September 2014 as an alternative to warfarin for treatment of venous thromboembolism... 
anticoagulation, edoxaban, venous thromboembolism
Journal Article
European heart journal, ISSN 1522-9645, 2019, Volume 40, Issue 19, pp. 1541 - 1550
Abstract Aims To investigate the relationship between body mass index (BMI) and outcomes in patients with atrial fibrillation (AF). Methods and results In the... 
Obesity | Stroke | Warfarin | Edoxaban | Atrial fibrillation | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | OBESITY PARADOX | DISEASE | PREVENTION | RISK | MECHANISMS
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2014, Volume 111, Issue 5, pp. 981 - 988
Summary Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs)... 
New Technologies, Diagnostic Tools and Drugs | EVENTS | METAANALYSIS | Atrial fibrillation | indirect comparisons | rivaroxaban | apixaban | edoxaban | ORAL ANTICOAGULANT DRUGS | WARFARIN | dabigatran | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | stroke prevention
Journal Article
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2019, Volume 74, Issue 1, pp. 104 - 132
Indications for measurement of NOAC serum levels might include: ▪Measurement of drug levels in patients undergoing urgent surgical procedures. ▪Uncovering... 
ACC/AHA Clinical Practice Guidelines | coronary artery disease | antiplatelet agents | thromboembolism | atrial flutter | stents | myocardial infarction | idarucizumab | rivaroxaban | cardioversion | atrial fibrillation | percutaneous coronary intervention | acute coronary syndrome | anticoagulants | dabigatran | sleep apnea | obesity | anticoagulation agents | risk factors | apixaban | stroke | edoxaban | warfarin | focused update | coronary heart disease | hypertension | CARDIAC & CARDIOVASCULAR SYSTEMS | STROKE PREVENTION | ORAL ANTICOAGULANT-THERAPY | ALL-CAUSE MORTALITY | ACUTE MYOCARDIAL-INFARCTION | ELUTING STENT IMPLANTATION | TRIPLE ANTITHROMBOTIC THERAPY | APPENDAGE CLOSURE | VITAMIN-K ANTAGONISTS | RISK-FACTOR | Thromboembolism - etiology | Thromboembolism - prevention & control | Atrial Fibrillation - therapy | Humans | Atrial Fibrillation - complications | Heart | Therapy | Cardiac arrhythmia | Surgical implants | Science | Drug delivery | Sleep apnea | Risk factors | Body mass index | Fibrillation | Publishing | Bridging | Defibrillators | Education | Low molecular weights | Quality | Implants | Flutter | Cardiology | Presidents | Anticoagulants | Evaluation | Task forces | Stroke | Electronic equipment | Warfarin | Electronic devices | Level (quantity) | Advisors | Implantation | Management | Patients | Appendix | Heart valves | Serum levels | Scientific papers | Medicine | Weight control | Body mass | Pacemakers | Body size | Documents | Writing | Dialysis | Diagnostic systems | Internet | Clinical medicine | Heparin
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 15, pp. 1406 - 1415
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2019, Volume 140, Issue 2, pp. e125 - e151
Journal Article